Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has shared an announcement.
PolyNovo’s 2025 Annual Report highlights its strategic focus on expanding global reach and product offerings, particularly with NovoSorb MTX. The company is enhancing its market position by scaling operations and driving growth through innovation, which is expected to benefit stakeholders by improving patient outcomes and increasing market penetration.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo, headquartered in Melbourne, Australia, is a medical technology company specializing in the management of acute and complex wounds. The company offers innovative product solutions such as NovoSorb BTM and NovoSorb MTX, which enhance patient outcomes across a wide range of wounds. PolyNovo has treated over 84,000 patients in 46 countries and is expanding its global presence through new products and clinical indications.
YTD Price Performance: -25.25%
Average Trading Volume: 2,666,783
Technical Sentiment Signal: Hold
Current Market Cap: A$1.05B
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.